5:40 PM
 | 
Oct 18, 2018
 |  BC Innovations  |  Emerging Company Profile

Altheia: Proliferating PD-L1

How Altheia is boosting PD-L1 expression to treat autoimmune diseases

Rather than blocking PD-L1 to treat cancer, Altheia Science s.r.l. is increasing expression of PD-L1 via a cell therapy to promote immune tolerance in autoimmune diseases, starting with Type I diabetes and multiple sclerosis.

Altheia was founded by tech transfer company AurorA-TT in 2017 with rights to IP from Boston Children’s Hospital covering PD-L1-expressing hematopoietic stem cells (HSCs).

Chairman and CEO Paolo Rizzardi noted that no approved therapies for Type I diabetes or MS target the root cause of the disease processes.

The standard of care for Type I diabetes is lifelong glucose monitoring and management with insulin injections. In MS, despite the availability of marketed disease-modifying therapies, many patients continue to progress.

Altheia is aiming to tamp down the...

Read the full 594 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >